An anonymous director reports

EMERALD HEALTH THERAPEUTICS ANNOUNCES SECONDARY OFFERING

Emerald Health Sciences Inc. has entered into a share purchase agreement with a single Canadian institutional accredited investor in connection with a secondary offering of common shares of Emerald Health Therapeutics Inc. Pursuant to the share purchase agreement, the investor will purchase 2.8 million common shares of the company from the selling shareholder at a price of $2.50 per secondary share.

The selling shareholder will receive all of the net proceeds from the secondary offering. No securities are being sold by the company.

In connection with the secondary offering, the company has agreed to file a shelf prospectus supplement qualifying the secondary shares for distribution in each of the provinces of Canada, except Quebec, in accordance with National Instrument 44-101 Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.

The closing date of the secondary offering is expected to be on or about Jan. 16, 2019, and is subject to customary closing conditions.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis. Its 50-per-cent-owned Pure Sunfarms joint venture in British Columbia is completing the conversion of its 1.1-million-square-foot (25-acre) greenhouse for cannabis cultivation in the Lower Mainland and its Agro-Biotech operation in Quebec is completing its 75,000-square-foot indoor facility. Commercial production is expanding in both facilities. In addition, Emerald secured over 500 acres of hemp harvest in 2018 and has contracted for approximately 1,000 acres in 2019 to 2022, with the objective of extracting low-cost cannabidiol.

We seek Safe Harbor.